Cargando…
Apatinib mesylate tablet in the treatment of advanced malignant melanoma
BACKGROUND: Observing and studying clinical efficacy and safety of apatinib mesylate tablet in the treatment of advanced malignant melanoma (MM). METHODS: Retrospectively analyzing the clinical data of 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126500/ https://www.ncbi.nlm.nih.gov/pubmed/30214239 http://dx.doi.org/10.2147/OTT.S175507 |
_version_ | 1783353340267069440 |
---|---|
author | Yang, Lingge Zhu, Huiyan Luo, Peng Chen, Shiqi Xu, Yu Wang, Chunmeng |
author_facet | Yang, Lingge Zhu, Huiyan Luo, Peng Chen, Shiqi Xu, Yu Wang, Chunmeng |
author_sort | Yang, Lingge |
collection | PubMed |
description | BACKGROUND: Observing and studying clinical efficacy and safety of apatinib mesylate tablet in the treatment of advanced malignant melanoma (MM). METHODS: Retrospectively analyzing the clinical data of 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January 2018. All patients took 500 mg of apatinib mesylate tablets per day. The efficacy should be evaluated according to RECIST 1.1 criteria. Adverse events (AEs) should be graded according to NCI-CTCAE 4.0. RESULTS: There were two cases of partial remission (PR), 11 of stable disease (SD) and nine of progressive disease (PD) in the 22 patients with advanced MM, where the objective remission rate (ORR) was 9.1% and the disease control rate (DCR) was 59.1%. The median progression-free survival (PFS) was 7.5 months, and the 6-month progression-free survival rate (PFR) was 54.7%. Six patients died and the overall survival (OS) was not reached. AEs were controllable and all were in Grade 1–3. CONCLUSION: Apatinib mesylate tablets have a certain curative effect on patients with malignant melanomas of Stage IV who failed conventional chemotherapy. Apatinib mesylate tablets at a daily dose of 500 mg are well tolerated by most patients. |
format | Online Article Text |
id | pubmed-6126500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61265002018-09-13 Apatinib mesylate tablet in the treatment of advanced malignant melanoma Yang, Lingge Zhu, Huiyan Luo, Peng Chen, Shiqi Xu, Yu Wang, Chunmeng Onco Targets Ther Case Series BACKGROUND: Observing and studying clinical efficacy and safety of apatinib mesylate tablet in the treatment of advanced malignant melanoma (MM). METHODS: Retrospectively analyzing the clinical data of 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January 2018. All patients took 500 mg of apatinib mesylate tablets per day. The efficacy should be evaluated according to RECIST 1.1 criteria. Adverse events (AEs) should be graded according to NCI-CTCAE 4.0. RESULTS: There were two cases of partial remission (PR), 11 of stable disease (SD) and nine of progressive disease (PD) in the 22 patients with advanced MM, where the objective remission rate (ORR) was 9.1% and the disease control rate (DCR) was 59.1%. The median progression-free survival (PFS) was 7.5 months, and the 6-month progression-free survival rate (PFR) was 54.7%. Six patients died and the overall survival (OS) was not reached. AEs were controllable and all were in Grade 1–3. CONCLUSION: Apatinib mesylate tablets have a certain curative effect on patients with malignant melanomas of Stage IV who failed conventional chemotherapy. Apatinib mesylate tablets at a daily dose of 500 mg are well tolerated by most patients. Dove Medical Press 2018-08-31 /pmc/articles/PMC6126500/ /pubmed/30214239 http://dx.doi.org/10.2147/OTT.S175507 Text en © 2018 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Series Yang, Lingge Zhu, Huiyan Luo, Peng Chen, Shiqi Xu, Yu Wang, Chunmeng Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title | Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title_full | Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title_fullStr | Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title_full_unstemmed | Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title_short | Apatinib mesylate tablet in the treatment of advanced malignant melanoma |
title_sort | apatinib mesylate tablet in the treatment of advanced malignant melanoma |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126500/ https://www.ncbi.nlm.nih.gov/pubmed/30214239 http://dx.doi.org/10.2147/OTT.S175507 |
work_keys_str_mv | AT yanglingge apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma AT zhuhuiyan apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma AT luopeng apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma AT chenshiqi apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma AT xuyu apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma AT wangchunmeng apatinibmesylatetabletinthetreatmentofadvancedmalignantmelanoma |